Skip to main content

Advertisement

SpringerLink
Log in

Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To determine the prevalence of dyslipoproteinemias and their related factors in a Brazilian systemic lupus erythematosus (SLE) population, fasting lipids were measured in 185 female SLE outpatients. Age, BMI, smoking, post-menopausal status, presence of diabetes and hypertension, SLE duration, number of ARA criteria, drug treatment and disease activity (by SLEDAI) were registered. Statistics included uni and multivariate logistic regression. Eighty-nine patients (48.1%) had hypercholesterolemia, 55 (29.7%) had hypertriglyceridemia and 109 (58.9%) had either. On multivariate analysis, 24-h proteinuria (OR = 2.08, 95% CI: 1.11–3.88), BMI (OR = 1.08, 95% CI: 1.01–1.16) and post-menopausal status (OR = 2.48, 95% CI: 1.25–4.92) were associated with hypercholesterolemia. Disease activity was related to low HDL-cholesterol (OR = 2.59, 95% CI: 1.20–5.58) and, in pre-menopausal patients, also to hypertriglyceridemia (OR = 1.16, 95% CI: 1.03–1.30). Antimalarial use was protective for hypertriglyceridemia (OR = 0.44, 95% CI: 0.22–0.90). In conclusion, the increased prevalence of dyslipoproteinemias is due to proteinuria, obesity and SLE activity. Antimalarials have beneficial effect on lipid profile that may be due to reduction in disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shattner A, Liang MH (2003) The cardiovascular burden of lupus. Arch Intern Med 163:1507–1510

    Article  Google Scholar 

  2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côté R, Grover SA, Fortin PR, Clarke AE, Senecal JL (2001) Traditional Framinghan risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331–2337

    Article  PubMed  CAS  Google Scholar 

  3. Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519

    Article  PubMed  CAS  Google Scholar 

  4. Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in systemic lupus erythematosus. J Rheumatol 21:1264–1267

    PubMed  CAS  Google Scholar 

  5. Tan EN, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  PubMed  CAS  Google Scholar 

  6. Bombadier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–640

    Article  Google Scholar 

  7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285:2486–2497

    Article  Google Scholar 

  8. Gladman DD, Urowitz MB (1987) Morbidity in systemic lupus erythematosus. J Rheumatol 14(Suppl 13):223–226

    Google Scholar 

  9. Manzi S, Meilahn EN, Rairia JE, Conte CG, Medsger Jr TA, Jansen-McWilliams L,D’Agostinho RB, Kuller LH (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415

    PubMed  CAS  Google Scholar 

  10. Petri M (2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:170–175

    Article  PubMed  CAS  Google Scholar 

  11. Borba EF, Bonfa E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease activity and cardiolipin antibodies. Lupus 6:533–539

    Article  PubMed  CAS  Google Scholar 

  12. Svenungsson E, Gunnarsson I, Fei G-Z, Lunberg IE, Klareskog L, Frostegard J (2003) Elevated triglycerides and low level of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533–2540

    Article  PubMed  CAS  Google Scholar 

  13. Al-Khalili F, Svane B, Jansky I, Ryden L, Orth-Gomer K, Schenck-Gustafsson K (2002) Significant predictors of poor prognosis in women aged ≤65 years hospitalized for acute coronary event. J Intern Med 252:561–569

    Article  PubMed  CAS  Google Scholar 

  14. Siripaitoon B, Osin M, Vongthavaravat V, Akkasilpa S, Deesomchok U (2004) The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus. Lupus 13:961–968

    Article  PubMed  CAS  Google Scholar 

  15. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363

    Article  PubMed  CAS  Google Scholar 

  16. Petri M (1996) Hydroxychloroquine use in Baltimore Lupus Cohort: effects on lipids, glucose, and thrombosis. Lupus 5(Suppl 1):S16–S22

    Article  PubMed  CAS  Google Scholar 

  17. Hodis HN, Quismorio Jr FP, Wickhan E, Blankenhorn DH (1993) The lipid, lipoprotein and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 20:661–665

    PubMed  CAS  Google Scholar 

  18. Rahman P, Gladman DD, Urowitz MB, Yeun K, Hallett D, Bruce IN (1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroids drugs. J Rheumatol 26:325–330

    PubMed  CAS  Google Scholar 

  19. Petri M, Lakatta C, Magder L, Goldman D (1994) Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96:254–259

    Article  PubMed  CAS  Google Scholar 

  20. Bruce IN, Urowitz MB, Gladman DD, Hallett DC (1999) Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 26:2137–2143

    PubMed  CAS  Google Scholar 

  21. Petri M, Spence D, Bone LR, Hochberg MC (1992) Coronary artery disease risk factors in the John Hopkins Lupus cohort: prevalence, recognition by patients, and preventive practices. Medicine 71:291–302

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Clementino Fraga Filho University Hospital, Medical School, Federal University of Rio de Janeiro, Rua Cróton, 72, Jacarepagua, CEP 22750-240, Rio de Janeiro, Brazil

    Claudia R. L. Cardoso, Flávio V. Signorelli, Jose A. Papi & Gil F. Salles

Authors
  1. Claudia R. L. Cardoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Flávio V. Signorelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose A. Papi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gil F. Salles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia R. L. Cardoso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cardoso, C.R.L., Signorelli, F., Papi, J.A. et al. Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Rheumatol Int 28, 323–327 (2008). https://doi.org/10.1007/s00296-007-0447-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-007-0447-x

Keywords

Search

Navigation